Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

ng statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.____________________________(1) Rossignol JF. Thiazolides: A new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009;5:667-674.(2) Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res. 2008;77:56-63.(3) Korba BE, Elazar M, Lui P, et al. Studies of the potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069-4071.(4) Yon C, Viswanathan P, Rossignol JF, Korba BE. Resistance to nitazoxanide is associated with alterations in the host and not the virus in HCV replicon-containing cultures. Submitted for publication.(5) Korba BE, Elazar M, Liu P, et al. Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology. 2008;48(suppl):356A.(6) Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-580.(7) Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in patients with chronic hepatitis C genotype 4 treated with nitazoxanide plus peginterferon alfa-2a with or with
'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) has announced ... Application, End-User & by Region - Global Trends & Forecast ... market is projected to reach about $2.5 Million by 2020, ... rising opportunities in countries such as India ... , and Brazil . In 2013, the ...
(Date:7/2/2015)... , July 2, 2015  The Green Exchange, ... the world,s first HIPAA compliant mobile app that connects ... farm-to-table fresh medical marijuana, announced today that their service ... Unlike Eaze, Meadow and more than half a dozen ... last year, Loud Cannabis is unique in that it ...
(Date:7/2/2015)... , July 2, 2015   Decision Resources ... retinal specialists identify less frequent dosing as the ... due to the burden on both patients and ... growth factor (VEGF) injections, which are the current ... abicipar pegol, which is in development for dosing ...
Breaking Medicine Technology:Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... , EXTON, Pa., Dec. 23 BioTrends Research Group, Inc. ... ®: Simponi and Cimzia report. ... 2009. BioTrends also conducted qualitative interviews with a subset (n=20) ... sales and marketing messages being employed to differentiate the products. ...
... , , , , ... /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin Board: CHME) ("China ... prescription and over the counter pharmaceuticals,traditional Chinese medicines (TCM), ... today announced that Richard P. Wu,has resigned as Chief ...
Cached Medicine Technology:Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 2Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 3China Medicine Announces Changes to Management Team 2China Medicine Announces Changes to Management Team 3
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief operating officer recruitment for Nicklaus Children’s Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... ... 2015 , ... Throughout the month of April, Casey’s General Stores invited customers ... Tuesday, July 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a ... a national nonprofit dedicated to restoring a sense of self, restoring the family unit, ...
(Date:7/2/2015)... ... July 02, 2015 , ... AvePoint Public Sector, Inc., a ... platforms and devices, today announced it was named the recipient of the 2015 GTRA ... award, given out by the Government Technology Research Alliance (GTRA), was presented June 29 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it has made two key appointments at ... General Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid ...
Breaking Medicine News(10 mins):Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... Arizona State University has used molecular biology tricks to create ... the ones that occurred naturally. ,John ... proteins in a fraction of the three billion years it ... to some surprisingly new lessons on how to optimize proteins ...
... University of Nottingham experts have joined forces with Canadian ... weapons in the fight against food poisoning . ... to develop methods for the control of Campylobacter ... England and Wales, according to the Health Protection Agency. ...
... a child is a uniquely enjoyable process. Why spoil it ... midwives, ask freebirthers . ,Delivering their own babies ... "fearmongering" by doctors and midwives and confidently catch their own ... uses the same hormones as lovemaking - so why would ...
... expectant mothers who smoke during pregnancy may be exposing ... disorder (ADHD), according to a study published in the ... prenatal exposure to smoking in the mothers womb puts ... ,During the course of study, the ...
... years ago, retail pioneer and philanthropist A. Alfred Taubman lost ... fatal disease thats better known as Lou Gehrigs disease or ... Sen. Jacob Javits slowly succumb to the nerve-killing condition has ... him to support ALS research at the University of Michigan ...
... seeking to prosecute director Michael Moore for taking volunteers on ... admission from New Yorks civic authorities. ,City's chief ... from the twin towers contributed to the death of Felicia ... Sept. 11 as she ran from her office a block ...
Cached Medicine News:Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:Delivering Baby, the Natural Way. 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 3Health News:Death from Exposure to WTC Dust Confirmed 2
... hydrophilic acrylic IOL is the newest advance ... with the patient and surgeon in mind. ... optic polymerically crosslinked with PMMA haptics to ... excellent visual performance and biocompatibility. The high ...
... : the 1st monobloc hard ... an exclusive and patented process ... designed the first single piece ... the FZ60. This technology warrantes ...
TRIPODE Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
Medicine Products: